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Andrew Feinberg shares his views on the field of
cancer epigenetics, from its beginnings to the most
exciting recent findings.for a second postdoc to pursue cancer genetics and epi-Introduction
Andrew Feinberg, MD, MPH (Figure 1), is Director of
the Center for Epigenetics at the Johns Hopkins School
of Medicine, Maryland, USA. From the beginning of the
field of cancer epigenetics right through to his current
work, he has been a source of pioneering ideas about
how changes in DNA methylation influence cancer.
1) What inspired you to study the role of DNA
methylation in cancer?
After medical school in the late 1970s, I did a postdoc on
the slime mold Dictyostelium discoideum, investigating
cell fate commitment and migration. I had developed a
method for purifying cells that were committed to differ-
entiation into the two mature cell types, spore and stalk,
while they were still undifferentiated slug cells, but already
committed to their destiny. In other words, there was a
form of non-genetic memory that was stably inherited
during cell division. This was an example of epigenetics,
although the term was not widely used at the time.
A year later, I did an MPH (Master’s in Public Health)
in quantitative areas of epidemiology, biostatistics and
biomedical engineering, still looking for a research direc-
tion. During that year, I happened to hear a lecture by
Don Coffey on cancer cells and tumor cell heterogeneity.
After his talk, I told him that my work on Dictyostelium
pluripotency was really the same thing that he was talk-
ing about in human cancer. There had to be some non-
genetic information that was stably inherited but at the
same time subject to plasticity. This led to a term paperCorrespondence: afeinberg@jhu.edu
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o/1.0/in which I argued that the causes of cancer are both gen-
etic and epigenetic. Don also introduced me to Bert
Vogelstein, who at the time was working on DNA repli-
cation and loop topology in another slime mold, Phy-
sarum polycephalum. Bert kindly agreed to take me on
genetics, as he was much more interested in cancer than
in Physarum.
This was very lucky for me because I just happened to
land in the lab of a wizard. We chose colon cancer as a
model because of what turned out to be a mistake in
someone else’s Nature paper. This paper presumed to
show widespread gene rearrangements in colon cancer
compared to matched normal mucosa of the same tissue
type, but it turned out that the normal tissues had been
contaminated by Escherichia coli. In contrast to the ab-
sence of widespread gene rearrangements, the evidence
for altered DNA methylation was overwhelming. I still
remember when I got the first Southern blot showing al-
tered DNA methylation in cancer. I told Bert in the
stairway to radiation oncology where we used to develop
the blots because we couldn’t afford a developer. We
knew we had something important - the data were just
screaming off the film.2) It’s more than 30 years since your Nature paper with
Bert Vogelstein showed that some genes in human
cancer cells were hypomethylated compared to their
normal counterparts. What impact did that work have on
the field?
Well, there was no field before that. People had not ex-
amined any epigenetic mark comparing human cancers
to matched normal tissues from which they arose. We
had a long conversation about how to label the figures
and decided on ‘N’ (for normal) and ‘C’ (for cancer) -
this became a kind of trademark through many publica-
tions. Also at the time, there was a huge unsolved prob-
lem regarding how cancers acquire properties that are
normal in other cell types at other stages of develop-
ment. As DNA methylation had already been linked to. The licensee has exclusive rights to distribute this article, in any medium, for 12
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http://genomemedicine.com/content/6/5/36normal differentiation and gene expression, the study
suggested a mechanism for abnormal gene expression in
cancer and tumor cell heterogeneity.
3) Do we understand yet how altered DNA methylation
contributes to cancer?
The discovery that we reported in Nature was about
methylation changes per se, not just hypomethylation.
The point was that changes in methylation would have
effects on gene regulation. There have been many papers
showing gene activation or dysregulated expression in
cancer. A few years after our paper [1], Horsthemke and
others [2] identified hypermethylation of tumor suppres-
sor genes. But recent data, such as Richard Meehan’s [3],
suggest that much of this epigenetic silencing is a mani-
festation of pre-existing chromatin changes at silenced
genes in the normal tissues from which the cancer
arises. Moreover, the ‘CIMP’ (CpG island methylator
phenotype) seems to be directly downstream of signaling
pathway mutations [4]. On the other hand, the hypo-
methylated domains seem to correspond to important
regions of nuclear structure. We have learned a great
deal more about this hypomethylation from recentwhole-genome studies. The hypomethylated domains
correspond to nuclear domains of heterochromatin that
we identified earlier [5] and termed LOCKs (large orga-
nized chromatin lysine modifications; which others call
LADs (lamin-associated domains)) or to the partially
methylated domains in normal cells identified by Lister
and colleagues [6]. The hypomethylation occurs very
early in cancer (for example, in Epstein-Barr virus im-
mortalized cells or in premalignant adenomas) and it
leads to highly variable expression of the genes that are
activated. We think, therefore, that disrupted methyla-
tion is a major factor in tumor cell heterogeneity, which
is what motivated me to study this area decades ago.
Winston Timp, Rafa Irizarry and I are working on the
possible relationship between the local small changes in
methylation - hypomethylated shores and hypermethy-
lated islands - and the large hypomethylated block do-
mains. In other work, we have found that epithelial
mesenchymal transition involves the transient ‘un-
LOCK-ing’ of these same domains [7]. So I think that
cancer involves the hijacking of a normal mechanism for
increasing the variance of gene expression - increased
cellular plasticity - that involves these large domains and
that is normally involved in processes such as injury re-
sponse or normal cellular migration. That would go a
long way toward explaining things like chemotherapy re-
sistance. Of course the epigenetic changes, although in
part probably primary, are also largely driven by muta-
tions during tumor progression [8].4) What have been the most exciting advances in the
field in the past couple of years?
There are thousands of papers a year now, so it’s hard to
single out particular papers, but there are three exciting
areas that are quite new. First are the many discoveries
of mutations in chromatin and methylation modifiers in
cancer. These appear important in solid tumor progres-
sion but may also be initiating events in some leukemias
and pediatric solid tumors. Second is the genome-scale
analysis of epigenetics in cancer, which has changed our
perspective enormously. We now realize that cancer is
in large part a disease of the epigenome. In addition to
our own work described above, I’m very excited by the
results of ENCODE and other large-scale projects that
provide potential targets for epigenetic disruptions in
cancer. These include the super-enhancers (discovered
by Rick Young and others) as well as long RNAs and
microRNAs. And of course the new epigenetically driven
ependymoma story from the Korshunov-Taylor group
[9] is very gratifying, as is the finding from the Yamada
group that simply disrupting reprogramming factors
during embryogenesis leads to Wilms tumors [10]. It fits
our epigenetic progenitor model [11] beautifully.
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ways of thinking about cancer epigenetics. Have you
encountered resistance or controversy along the way?
Always. There are two big differences for me between
then and now, however. First is my own reaction. I used
to get upset with my papers being rejected and now I
shrug it off - that’s either maturity or dementia. Second
are all the friends I have made in my field who have suf-
fered the same fate. I don’t actually think this is a case of
our treating each others’ papers poorly (like the comic
book opossum, Pogo, who famously said ‘We have met
the enemy and he is us’). Rather, I think there remains a
great deal of opposition to translational epigenomics
from some members of the classical transcription factor
community - it’s not a reach to say so, as they are quite
vocal about it.
I think the epigenetic progenitor model [11] changed a
lot of people’s minds though. The idea is that cancer in-
volves the polyclonal epigenetic disruption of stem or pro-
genitor cells, and that tumor cells develop on an
epigenetically predisposed background. There were cer-
tainly early examples of work showing this, such as loss of
imprinting in Beckwith-Wiedeman syndrome and com-
mon adult tumors, and Jean-Pierre Issa’s work on age-
related epigenetic changes in tissues at risk of cancer. The
model is strongly supported by the recent discoveries of
primary epigenetic cancers, by the reprogramming factor
study and by the papers from Teschendorff and colleagues
[12] reporting the presence of epigenetically stochastic
cells in normal tissue years before tumors develop.
6) In 2011 you described increased epigenetic variability
in cancer, as well as absolute differences from normal
cells. What implications does this have for treating
cancer?
So this is what I spend most of my time on these days.
Readers should please not confuse my enthusiasm for
my ideas with any sense of certainty on my part that
they are right. The idea grew from a possible insight into
the role of stochasticity in evolution. That is, there
would be a selective advantage for genetic variants that
increase epigenetic and phenotypic plasticity -aside from
mean effects - for genes in which the selective advantage
or disadvantage changes unpredictably but recurrently
because of a changing environment. In evolution, this
would be analogous to something like the availability of
nutrients affecting either a positive or negative advan-
tage for size. But in cancer, increased epigenetic plasti-
city appears to provide the cell with an enormous
advantage. The idea is that this allows for rapid selection
in a highly changing environment - such as fluctuating
oxygen levels or a variable tissue microenvironment
[13]. Indeed we have found striking epigenetic variability
in at least solid tumors, more so than even the meanchanges in epigenetic marks between cancer and normal.
This variability appears to have a structural basis as well
in the LOCKs and blocks described above [14].7) What challenges need to be addressed for our
understanding of the role of DNA methylation in cancer
to be translated to clinical application?
At one level - none. I’m not trying to be flippant, but so
much of cancer treatment has already been reconsidered
mechanistically, and anything that might be helpful to
mitigate this terrible disease should at least be considered.
Even azacytidine probably acts immunologically rather
than on tumor suppressor genes as its main effect. And
using epigenetic variability as a risk marker in tissues
shows promise in Teschendorff ’s work. For therapy, I’m
wondering if some of the drugs now in use or develop-
ment in fact affect the large heterochromatin domains that
are destabilized in cancer. If we can develop assays for
this, we might be able to develop new lead compounds.
For basic science, the most exciting possibility coming
down the road is the possibility of a 3D nucleome initia-
tive from the NIH Director’s Common Fund Program,
which could relate epigenomics to nuclear structure and
function mechanistically at a single-cell level.8) Has understanding the role of DNA methylation in
cancer given us insights into the epigenetic basis of other
complex diseases?
Absolutely. The approach to integrating genetics, exposure,
and gene function that is so central to cancer epigenetics is
already bearing fruit in other common disease studies, such
as Stephan Beck’s work on diabetes, Tim Spector’s studies
of twins, our work on autoimmune disease, and Manel
Esteller’s and others’ work on aging.
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